Plasma p-tau181/Aβ_1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ_1-42 and future cognitive decline.

ABSTRACT:

Background

In Alzheimer's disease (AD), plasma amyloid beta (Aβ)_1-42 and phosphorylated tau (p-tau) predict high amyloid status from Aβ positron emission tomography (PET); however, the extent to which combination of these plasma assays can predict remains unknown.

Methods

Prototype Simoa assays were used to measure plasma samples from participants who were either cognitively normal (CN) or had mild cognitive impairment (MCI)/AD in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.

Results

The p-tau181/Aβ_1-42 ratio showed the best prediction of Aβ-PET across all participants (area under the curve [AUC] = 0.905, 95% confidence interval [CI]: 0.86-0.95) and in CN (AUC = 0.873; 0.80-0.94), and symptomatic (AUC = 0.908; 0.82-1.00) adults.

SUBMITTER: Fowler CJ 

PROVIDER: S-EPMC9695763 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature